PortfoliosLab logo
HALO vs. RXRX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between HALO and RXRX is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

HALO vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Halozyme Therapeutics, Inc. (HALO) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

-100.00%-50.00%0.00%50.00%December2025FebruaryMarchAprilMay
45.94%
-85.97%
HALO
RXRX

Key characteristics

Sharpe Ratio

HALO:

1.38

RXRX:

-0.53

Sortino Ratio

HALO:

2.14

RXRX:

-0.46

Omega Ratio

HALO:

1.32

RXRX:

0.95

Calmar Ratio

HALO:

1.94

RXRX:

-0.56

Martin Ratio

HALO:

5.12

RXRX:

-1.55

Ulcer Index

HALO:

12.84%

RXRX:

32.81%

Daily Std Dev

HALO:

44.71%

RXRX:

93.12%

Max Drawdown

HALO:

-74.26%

RXRX:

-90.39%

Current Drawdown

HALO:

-3.44%

RXRX:

-89.38%

Fundamentals

Market Cap

HALO:

$7.56B

RXRX:

$2.32B

EPS

HALO:

$3.43

RXRX:

-$1.80

PS Ratio

HALO:

7.38

RXRX:

39.37

PB Ratio

HALO:

20.78

RXRX:

2.07

Total Revenue (TTM)

HALO:

$1.08B

RXRX:

$59.76M

Gross Profit (TTM)

HALO:

$887.05M

RXRX:

-$46.00K

EBITDA (TTM)

HALO:

$530.80M

RXRX:

-$534.16M

Returns By Period

In the year-to-date period, HALO achieves a 41.66% return, which is significantly higher than RXRX's -35.06% return.


HALO

YTD

41.66%

1M

17.71%

6M

13.55%

1Y

61.22%

5Y*

23.55%

10Y*

16.03%

RXRX

YTD

-35.06%

1M

10.58%

6M

-36.65%

1Y

-48.89%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

HALO vs. RXRX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HALO
The Risk-Adjusted Performance Rank of HALO is 8989
Overall Rank
The Sharpe Ratio Rank of HALO is 9090
Sharpe Ratio Rank
The Sortino Ratio Rank of HALO is 8888
Sortino Ratio Rank
The Omega Ratio Rank of HALO is 8989
Omega Ratio Rank
The Calmar Ratio Rank of HALO is 9393
Calmar Ratio Rank
The Martin Ratio Rank of HALO is 8787
Martin Ratio Rank

RXRX
The Risk-Adjusted Performance Rank of RXRX is 1919
Overall Rank
The Sharpe Ratio Rank of RXRX is 2323
Sharpe Ratio Rank
The Sortino Ratio Rank of RXRX is 2525
Sortino Ratio Rank
The Omega Ratio Rank of RXRX is 2727
Omega Ratio Rank
The Calmar Ratio Rank of RXRX is 1717
Calmar Ratio Rank
The Martin Ratio Rank of RXRX is 66
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

HALO vs. RXRX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current HALO Sharpe Ratio is 1.38, which is higher than the RXRX Sharpe Ratio of -0.53. The chart below compares the historical Sharpe Ratios of HALO and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.50December2025FebruaryMarchAprilMay
1.38
-0.53
HALO
RXRX

Dividends

HALO vs. RXRX - Dividend Comparison

Neither HALO nor RXRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

HALO vs. RXRX - Drawdown Comparison

The maximum HALO drawdown since its inception was -74.26%, smaller than the maximum RXRX drawdown of -90.39%. Use the drawdown chart below to compare losses from any high point for HALO and RXRX. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-3.44%
-89.38%
HALO
RXRX

Volatility

HALO vs. RXRX - Volatility Comparison

The current volatility for Halozyme Therapeutics, Inc. (HALO) is 20.47%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 39.86%. This indicates that HALO experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%December2025FebruaryMarchAprilMay
20.47%
39.86%
HALO
RXRX

Financials

HALO vs. RXRX - Financials Comparison

This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M20212022202320242025
264.86M
14.75M
(HALO) Total Revenue
(RXRX) Total Revenue
Values in USD except per share items